Vascular Medicine News

Patients receiving daily tofacitinib doses of 10 mg for rheumatoid arthritis demonstrate an increased risk for venous thromboembolism and pulmonary embolism, compared with those taking TNF inhibitors, according to data.

ATLANTA — Among adults with mild to moderate hypertension, receiving text messages designed to cultivate spirituality was associated with an average 7 mm Hg decrease in systolic BP compared with no intervention, researchers reported.

ATLANTA — Telehealth visits with CV care teams initiated when patients with prior ACS experienced concerning symptoms reduced unnecessary readmissions, guided them when seeking emergency care and reduced CV events, a speaker reported.

Among adults with pulmonary arterial hypertension, patient characteristics, mortality and treatment varied across four U.S. census regions, according to results published in Annals of the American Thoracic Society.

Salt substitution may reduce the risk for all-cause and cardiovascular mortality, and it may also reduce the risk for major cardiovascular events, according to a systematic review and meta-analysis randomized controlled trials.

ATLANTA — Adults with uncontrolled and treatment-resistant hypertension saw a modest reduction in 24-hour ambulatory BP with alcohol-mediated renal nerve denervation, although other mixed findings complicate the picture, researchers reported.

ATLANTA — A screening study presented at the American College of Cardiology Scientific Session showed that there is a high prevalence of unrecognized heart disease among former National Football League players.

ATLANTA — In patients with ACS who underwent PCI, ticagrelor monotherapy after 1 month lowered bleeding risk by 55% compared with dual antiplatelet therapy for 12 months, according to the results of the ULTIMATE-DAPT trial.

ATLANTA — A single subcutaneous dose of zilebesiran, an investigational RNA interference agent, significantly reduced 24-hour mean ambulatory and office systolic BP at 6 months vs. placebo when added to other antihypertensive therapy.

ATLANTA — In the TACT2 trial, chelation therapy reduced levels of lead in the blood but did not improve cardiovascular outcomes for adults with diabetes and a prior heart attack.